Global Institute for Novel Nicotine (GINN)

This page was last edited on at

The Global Institute for Novel Nicotine (GINN) states that it is “a membership-based association dedicated to advancing collaborative standards, innovation, research, and advocacy in the field of alternative nicotine products.”123

Background

GINN launched in March 2024. Its original website (the-ginn.com) stated that it was “dedicated to positioning itself as the industry’s primary advocate for non-vaping reduced-risk products”3 and “communicating the public health benefits of switching from combustible tobacco to RRPs”.4

Its current website, ginn.global, states:1

“We advocate for and champion pouches, heated tobacco, and other emerging reduced-risk products (RRPs) on behalf of our members”

The GINN LinkedIn profile states that it supports the development of RRPs in order “to create a safer future for consumers worldwide.”2 It also states that it collaborates with “industry leaders, researchers, and policymakers to address regulatory challenges, promote harm reduction, and ensure responsible product development” and that its “commitment to collaboration and scientific integrity positions us as a trusted voice in the evolving landscape of tobacco harm reduction and nicotine innovation.”2

GINN was registered with UK Companies House in June 2024 as Global Int for Novel Nicotine, a Limited Liability Partnership.5In April 2025, GINN was added to the EU Transparency Register.67

Relationship to the Tobacco Industry

The director for GINN is a former employee of Philip Morris International (see below).

The GINN website states that “Admittance to membership is not permitted to any entity owned by multinational or transnational tobacco companies”.31 GINN has issued other statements with different wording. An e-mail sent to a UK academic in October 2024 stated that:

GINN’s membership excludes any involvement from Big Tobacco, in line with FCTC 5.3, ensuring that our efforts are fully aligned with public health principles8[emphasis in original]

In August 2024, Better Retailing reported GINN as saying that “it does not offer membership to or take funding from tobacco companies”,9

However, there are multiple connections between GINN and transnational tobacco companies (TTCs) via member companies and individuals.

People

Global Int for Novel Nicotine LLP originally had two consultants as designated members, Shem Baldeosingh and David Roach.

Shem Baldeosingh

Director General of GINN since March 2024.1011 He is described on the website as ‘Chief Advocate’ of GINN,12 and on the EU Transparency register as the person responsible for EU relations.67 He had previously been employed as a public affairs manager for Philip Morris International (PMI) until September 2022,11 the same month he set up PR company Nexum Consulting.13 In June 2025, Nexum Consulting was appointed as a designated member for GINN.5 Baldeosingh’s profile on the GINN website does not refer to PMI or Nexum, or detail his other affiliations:10

  • Nexum Consulting also operates NordicPouch New Zealand, an online nicotine pouch store.14
  • Baldeosingh is director of a company called SmokeFree Innovation, registered in New Zealand in 2025.111516 The company LinkedIn profile states that it operates across the Asia Pacific region.1718
  • New Zealand company records indicate that Baldeosingh is also director of SmokefreeRX,161920 a telehealth company based in Sydney, Australia, where it was registered in 2024.192021
  • From 2019 to 2020, Baldeosingh worked as Government Affairs Consultant for Mission Limited,11 New Zealand distributor for Chinese e-cigarette brand RELX.2223

David Roach

Roach previous consulted for nicotine company ANDS,24 and, as reported by The Guardian newspaper, is linked to the anti-WHO campaign ‘Action on World Health’, launched by UK politician Nigel Farage in May 2024.25 Roach left GINN on 29 Nov 2024.5 Roach is no longer listed as a designated member of GINN. He remains designated member for the LLP behind Action on World Health.26

Current members of the GINN leadership team are listed on the GINN website. See Relevant Links below.

A disclosure policy states that, apart from the Director, all member of the leadership team are volunteers and “no member of the GINN leadership team, including Steering Committee members, the Science and Standards Committee and associated Working Group Chairs, receives a salary from the organization.”27 It also states that the leadership is committed to “[d]isclosing relevant external business interests to prevent conflicts”.27

The sections below on GINN Focal Points and the Science and Standards Committee detail further connections to tobacco companies and industry activities.

Member Companies

As of November 2024, GINN listed its members on its website. These included, among others,  nicotine manufacturers and distributors of nicotine products (see Image 1 below).28

Image 1: Global Institute for Novel Nicotine Membership list, the-ginn.com website, screenshot captured 1 November 202428

Further information about the work of some of these companies was published on the GINN website:2930

For example, Inter Scientific, which provides services relating to the regulation of nicotine and heated tobacco products (HTPs),31 was profiled,30 and represented GINN in an interview with the BBC soon after joining.3233

However the website did not appear to indicate that another member company Labstat has worked with PMI,34 and Swedish Match (now also owned by PMI).35

Another member company ACCORTO,36 has worked on US Pre-Market Tobacco Product Applications (PMTAs) for HTPs, although it does not specify its clients, or the products, on its website.37

Science and Standards Committee members

In 2024, GINN’s website listed members of its Science and Standards Committee, and its five working groups:38

  • Product Composition and Design Standards
  • Consumer Behavior and Youth Access Prevention
  • Toxicity and Health
  • Regulatory Compliance and Standards
  • Marketing and Communications

The list of committee members included ex-employees of TTCs and related companies:

  • Marina Murphy – has worked for BAT & JUUL Labs.39
  • Waqas Khan – has worked for BAT & JUUL Labs.40
  • Markus Lindblad – has worked for BAT.41

Others have received tobacco industry funding, or published research papers with tobacco companies:

As of 2025, GINN did not list all its working groups, and the only member of the Science and Standards committee named on the GINN website is the Chair, Dr. Nveed Chaudhary.10

Chaudhary’s profile on the GINN website states that he previously held roles at PMI, British American Tobacco (BAT), and Imperial Brands, and that he runs NexCentra Consulting which works on “advancing credible, science-based harm reduction worldwide.”1044

Focal Points

As of 2025, ‘Focal points’ listed on the GINN website included:45

  • Joel Rubenstein, GINN Focal Point. According to his LinkedIn profile, Rubenstein, has held Global Vice President roles at Aspeya Healthcare since April 2023, currently as  Category Head, Smoking Cessation.4647 Aspeya is wholly owned by PMI, and  Fertin Pharma is a subsidiary.4849 (PMI established Vectura Fertin Pharma in 2022, after its acquisition of pharmaceutical company Vectura. See Tobacco Company Investments in Pharmaceutical & NRT Products for more information.) Previously Rubenstein was President of Niconovum, which is wholly owned by Reynolds/BAT.46
  • Tautvydas Kviliūnas, Focal Point, GINN Lithuania, CEO of Global Snus, a ‘white label’ supplier of nicotine pouches.

For details of other focal points see the GINN website.

Activities

Lobbying on UK Tobacco and Vapes bill 

In August 2024, a Better Retailing article stated that GINN “urged the Government not to press ahead with flavour, packaging and display bans on vapes, nicotine pouches and heat-not-burn products”.9 Quoting Baldeosingh, that article went on to say:

The GINN representatives explained that many of the most experienced politicians in vaping and nicotine had lost their seats at the General Election, potentially creating an opportunity for a much wider consultation ahead of a new tobacco and vapes bill being brought forward by the new government.”9

In January 2025, GINN submitted a response to a consultation on the UK Tobacco and Vapes Bill.50 GINN argued that nicotine pouches, along with lozenges and gums, “should not be regulated in the same manner as combustible smoking products and nicotine vaping products”, and referred to an opportunity for “positive economic growth through product advancement”.50

Former MEP lobbying with GINN in EU

Johan Nissinen, a former Swedish Member of the European Parliament (MEP), became a member of GINN in November 2025.51 He is associated with lobbying by GINN in relation to the regulation of nicotine products in the EU.5253 In a LinkedIn post, GINN stated that Nissinen “helped open the right doors at the right time”.53 The Taxpayers Protection Alliance (TPA) gave Nissinen an award, citing his “persistent advocacy for tobacco harm reduction”.54

Events

Events attended by representatives of GINN include:

  • New Approaches Summit, New York, September 2024 – Baldeosingh (representing Nexum Consulting) spoke at this event, at the Harvard Club.55  A New Approaches Linkedin post described him as “a global leader in public affairs strategies, having occupied leadership roles in the UK, as well as serving as a strategic partner to leadership in the UK, Trinidad and Tobago, New Zealand, the Pacific Islands, and Australia”, and that he was “uniquely equipped to speak on the impacts of the Framework Convention for Tobacco Control (#FCTC) in the Caribbean”.55
  • This post did not mention his previous roles at PMI. Baldeosingh also attended the summit in 2023.56
  • World Vape Show, Dubai, June 2025 – several GINN members were listed on the programme in a panel discussion called ‘Next level of harm reduction’, with Baldeosingh listed as representing GINN.57 While his website bio stated that he had previously work with a ‘large multinational company’, it did not mention PMI.57
  • InterTabac, Dortmund, September 2025 – InterTabac describes itself as the “leading trade fair for tobacco products and smoking accessories”.58 The InterTabac website stated that GINN would be involved in two panels, one on “Innovating the Oral Nicotine Segment: Product Development & Consumer Trends” to be moderated by Chaudhary and another on “Navigating TPD3, Tobacco Excise Directive, and WHO FCTC COP11”. 5960

Relevant Link

Global Institute for Novel Nicotine website

Tobacco Tactics Resources

Tobacco Company Investments in Pharmaceutical & NRT Products

Tobacco Industry Interference with Endgame Policies

Harm Reduction

References

  1. abcGlobal Institute for Novel Nicotine, Pioneering a Fresh Perspective on Nicotine, ginn.global website, accessed October 2025
  2. abcGlobal Institute for Novel Nicotine (GINN), LinkedIn profile, accessed October 2025
  3. abcGlobal Institute for Novel Nicotine, Pioneering a Fresh Perspective on Nicotine, the-ginn.com website, archived 26 April 2024, accessed October 2025
  4. Global Institute for Novel Nicotine, About GINN: Changing the Narrative, the-ginn.com website, archived 23 November 2024, accessed October 2025
  5. abcGlobal Int for Novel Nicotine LLP, Company number OC452584, Companies House record, accessed July 2025
  6. abGlobal Institute for Novel Nicotine (GINN), EU Transparency Register entry, accessed February 2026
  7. abGlobal Institute for Novel Nicotine (GINN), LobbyFacts.eu, accessed 6 February 2026
  8. Subject: Introduction to the Global Institute for Novel Nicotine (GINN) – Exploring Potential Collaboration, e-mail dated 31 October 2024, supplied to Tobacco Tactics
  9. abcJ. Courtez, Vape bans will hinder efforts to cut smoking, Global Institute for Novel Nicotine warns, Better Retailing, 27 August 2024, archived January 2025, accessed August 2025
  10. abcdGlobal Institute for Novel Nicotine, Meet the GINN Leadership Team, ginn.global website, accessed July 2025
  11. abcdShem Baldeosingh, Linkedin profile, accessed February 2026
  12. Global Institute for Novel Nicotine, Welcoming Joel Rubenstien as GINN Focal Point, ginn.global website, accessed July 2025
  13. Nexum Consulting, Company number OC452584, Companies House record, accessed July 2025
  14. Nordicpouch New Zealand, website, undated, accessed 4 February 2026
  15. Smokefree Innovation Limited, Open Corporates, accessed February 2026
  16. abSmokefree Innovation Limited, company number 9291314, New Zealand Companies Register, registered 3 October 2025, accessed February 2026
  17. Smoke Free Innovation, LinkedIn profile, undated, accessed February 2024
  18. As of February 2026, the SmokeFree Innovation website did not appear to be operational
  19. abSmokefree Pty Ltd, ABN 27 681 495 045, Australian Government Business Register, registered 3 October 2025, accessed February 2026
  20. abSmokefree Pty Ltd ACN 681 495 045, Australian Securities and Investments Commission (ASIC) register, accessed February 2026
  21. SmokefreeRX, website, undated, archived 15 December 2024, accessed February 2026
  22. dun&bradstreet, Mission Limited, Dun & Bradstreet, undated, accessed 4 February 2026
  23. The New Zealand Herald, Vape device wins design award ,16 August 2020, accessed February 2026
  24. David Roach Consulting Ltd, Office of the Register of Consultant Lobbyists, register entry for January to March 2024, accessed July 2025
  25. R. Mason, Nigel Farage’s anti-WHO campaign has link to nicotine products industry, The Guardian, 21 November 2024, accessed July 2025
  26. Action on World Health LLP, Company no OC452205, Companies House record, accessed July 2025
  27. abGlobal Institute for Novel Nicotine, GINN Leadership Team Disclosure Policy, ginn.global website, accessed October 2025
  28. abGlobal Institute for Novel Nicotine, Members, the-ginn.com website, archived 1 November 2024, accessed July 2025
  29. Global Institute for Novel Nicotine, News, the-ginn.com website, archived 21 November 2024, accessed July 2025
  30. abGlobal Institute for Novel Nicotine, Inter Scientific Joins GINN To Further Tobacco Harm Reduction Mission, press release, 12 September 2024, archived 16 October 2024, accessed August 2025
  31. Inter Scientific, Regulatory Support for Nicotine, website, undated, accessed September 2025
  32. BBC, “What are the dangers of snus?”, Morning Live segment, Facebook, 23 September 2024
  33. Global Institute for Novel Nicotine, GINN Welcomes BBC Morning Live Film on Nicotine Pouches, press release, 12 September 2024, archived 16 October 2024, accessed August 2025
  34. Philip Morris International, Tobacco Heating System mainstream aerosol compared with reference cigarette smoke, PMI Science website, undated, archived 6 June 2022, accessed August 2025
  35. abLabstat/Swedish Match, Comparative Toxicity Assessment of the Harm Reduction Potential of Tobacco-Free Oral Nicotine Products, poster presentation, 10-14 March, available from labstat.com
  36. Accorto Joins Institute for Novel Nicotine, Tobacco Reporter, 5 September 2024, accessed August 2025
  37. Accorto, Pre-Market Tobacco Product Applications, website, undated, accessed August 2025
  38. Global Institute for Novel Nicotine, Science and Standards Committee, the-ginn.com website, archived 16 October 2024, accessed July 2025
  39. Murphy, Linkedin profile, undated, accessed August 2025
  40. Khan, Linkedin profile, undated, accessed August 2025
  41. M. Lindblad, Linkedin Profile, undated, accessed August 2025
  42. Caruso, R. Emma, A. Distefano et al, Comparative assessment of electronic nicotine delivery systems aerosol and cigarette smoke on endothelial cell migration: The Replica Project, Drug Test Anal, 2023; 15(10): 1164-1174, doi:10.1002/dta.3349
  43. B. Coffa, C. Coggins, M. Werley et al, Chemical, physical, and in vitro characterization of research cigarettes containing denicotinized tobacco, Regulatory Toxicology and Pharmacology, May 2016, doi:1016/j.yrtph.2016.05.016
  44. Nextra Consulting, The Age of Aligned Innovation Has Arrived, website, undated, accessed July 2025
  45. Global Institute for Novel Nicotine, Focal Points, ginn.global website, accessed August 2025
  46. abJoel Rubenstein, LinkedIn profile, accessed October 2025
  47. Global Institute for Novel Nicotine, Welcoming Joel Rubenstein as GINN Focal Point, ginn.global website, 30 June 2025, accessed July 2025
  48. Aspaya, Who we are, website, undated, accessed October 2025
  49. Aspaya Denmark A/S, Open Corporates profile, accessed October 2025
  50. abGlobal Institute for Novel Nicotine, Written evidence submission from Global Institute for Novel Nicotine (GINN) to the Tobacco and Vapes Public Bill Committee (TVB35), 5 January 2025, available from ginn.global.com and  bills.parliament.uk
  51. GINN, Welcoming Johan Nissinen to the Global Institute for Novel Nicotine (GINN), LinkedIn post,18 November 2025,accessed February 2026
  52. News – Former MEP Nissinen now a nicotine lobbyist, Tabaknee, website, 22 January 2026, accessed 4 February 2026
  53. abGINN, GINN’s Brussels Visit Boosts Momentum for Nicotine Harm Reduction LinkedIn post,December 2025, accessed February 202661 According to the EU Transparency Register, in December 2025 Nissinen and Baldeosingh met another MEP, to discuss “innovative nicotine products.”62European Parliament, Search MEP meetings | MEPs | European Parliament, undated, accessed 6 February 2026
  54. 63R.Marchand, Profile in Courage: MEP Johan Nissinen – Taxpayers Protection Alliance, Taxpayers Protection Alliance, October 30 2025, accessed 4 February 2026
  55. abNew Approaches Conference, New Approaches is pleased to welcome Shem Baldeosingh…, August 2024, Linkedin post, accessed August 2025
  56. New Approaches Conference, Agenda 2023, website, archived October 2023, accessed February 2026
  57. abWorld Vape Show, Panel discussion: Next level of harm reduction, 13 June 2025, website, archived 23 July 2024, accessed August 2025
  58. InterTabac, Website home page, undated, accessed August 2025
  59. InterTabac, Interbac Supporting Programme: First Speakers And Topics Have Been Confirmed, website, 10 July 2025, accessed August 2025
  60. InterTabac, 2FIRSTS | InterTabac Supporting Programme, 2Firsts, 22 July 2025, accessed 4 February 2026
.ttref-sup + .ttref-sup { margin-left: 2px; }